Albert David Q4 FY26 Results: Loss Rs 21.43 Crore
- May 13, 2026
- Posted by: Kunal Singla
- Category: News
Albert David Q4 FY26 results were announced on 12 May 2026, with the company reporting a consolidated net loss of Rs 21.43 crore for the quarter ended March 31, 2026. The Albert David Q4 FY26 performance will be assessed by investors against the broader macro backdrop of India’s economic recovery, sectoral dynamics in Pharmaceuticals, and management commentary on the FY27 outlook.
Click Here – Get Free Investment Predictions
Albert David reported a Q4 FY26 net loss of Rs 21.43 crore. The company operates in the pharmaceuticals and healthcare segment. The loss in the March quarter reflects operational and competitive challenges that the management is working to address in FY27.
Albert David Q4 FY26 Key Financial Highlights
The following table summarises key Albert David Q4 FY26 financial highlights as reported on 12 May 2026.
| Parameter | Q4 FY26 | Reference |
|---|---|---|
| Net Loss | Rs 21.43 crore | Prior year period |
| NSE Ticker | ALBERTDAV | Sector: Pharmaceuticals |
Screen the best stocks on the Univest Screener.
Albert David Q4 FY26 Profit Analysis
Albert David Q4 FY26 net loss of Rs 21.43 crore reflects a loss in Pharmaceuticals. The loss reflects ongoing challenges in the business that management is working to address. Investors will closely monitor management commentary on margin trajectory and FY27 guidance from these Albert David Q4 FY26 results.
The company operates in Pharmaceuticals, a sector that is closely watched for demand trends, margin recovery, and volume growth in the context of India’s overall economic momentum in FY27.
Revenue and Operating Performance in Albert David Q4 FY26
The revenue performance in Albert David Q4 FY26 reflects the operating dynamics of the Pharmaceuticals sector during the January to March 2026 quarter. The Albert David Q4 FY26 operating performance will be evaluated against the context of broader industry trends, raw material costs, and demand conditions in the company’s key markets.
Management commentary on volume growth, pricing power, margin trajectory, and order book position will be key inputs for analysts revising their FY27 estimates following these Albert David Q4 FY26 results.
Albert David Q4 FY26 Stock Price and Market Position
Albert David is listed on the NSE under the ticker ALBERTDAV and operates in the Pharmaceuticals sector. Following the Albert David Q4 FY26 results announcement on 12 May 2026, the stock will be assessed by the market based on the quarterly profitability trajectory, management commentary on FY27 outlook, and dividend decision. Investors should track live price movements and analyst rating changes on the Univest Screener.
Albert David FY27 Outlook
Post Albert David Q4 FY26 results, the key areas of investor focus for FY27 include management’s guidance on revenue growth, operating margin trajectory, capital expenditure plans, and demand visibility in the Pharmaceuticals sector. The company’s path to profitability and turnaround execution will be the primary focus for investors in FY27. The broader macroeconomic backdrop of India’s continued growth momentum, RBI rate cuts, and sectoral policy tailwinds will also shape the FY27 earnings outlook for Albert David.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on Albert David Q4 FY26 Results
What is Albert David Q4 FY26 net loss?
Ans. Albert David Q4 FY26 consolidated net loss is Rs 21.43 crore.
When did Albert David announce Q4 FY26 results?
Ans. Albert David announced Q4 FY26 results on 12 May 2026, through a board meeting held on the same date, with filings submitted to BSE and NSE thereafter.
What was Albert David revenue in Q4 FY26?
Ans. Albert David Q4 FY26 financial results were filed with BSE and NSE on 12 May 2026. Track live data on the Univest Screener.
What is the FY27 outlook for Albert David?
Ans. Post Q4 FY26 results, investors will closely monitor management guidance on revenue growth, margin trajectory, and capital allocation in the Pharmaceuticals sector for FY27.
Where can I track Albert David Q4 FY26 live price?
Ans. Track Albert David live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.
